Outlook Therapeutics (OTLK) Stock Forecast & Price Target

$5.28 +0.05 (+0.96%)

(As of 11/20/2024 ET)

Outlook Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Outlook Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for OTLK.

Consensus Price Target

$48.20
812.88% Upside

According to the 7 analysts' twelve-month price targets for Outlook Therapeutics, the average price target is $48.20. The highest price target for OTLK is $100.00, while the lowest price target for OTLK is $30.00. The average price target represents a forecasted upside of 812.88% from the current price of $5.28.

Get the Latest News and Ratings for OTLK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors.

OTLK Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	1 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	6 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$48.20	$48.20	$45.55	$92.00
Forecasted Upside	812.88% Upside	770.04% Upside	504.91% Upside	920.86% Upside
Consensus Rating	Buy	Buy	Moderate Buy	Hold

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

OTLK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

OTLK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Outlook Therapeutics Stock vs. The Competition

Type	Outlook Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	812.88% Upside	26,931.27% Upside	9.84% Upside
News Sentiment Rating	Neutral News See Recent OTLK News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/18/2024	BTIG Research 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00	+874.66%
9/3/2024	Ascendiant Capital Markets 2 of 5 stars		Lower Target	Buy ➝ Buy	$35.00 ➝ $33.00	+348.98%
8/16/2024	Chardan Capital 1 of 5 stars	D. Gataulin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00	+570.89%
8/15/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00	+308.72%
2/16/2024	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Chiang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
1/25/2024	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Dolliver Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40	+292.50%
Get the Latest News and Ratings for OTLK and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
1/25/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$40.00	+400.00%
8/30/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	K. Kluska Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$90.00 ➝ $20.00	+340.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:23 AM ET.

OTLK Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Outlook Therapeutics is $48.20, with a high forecast of $100.00 and a low forecast of $30.00.
: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Outlook Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OTLK shares.
: According to analysts, Outlook Therapeutics's stock has a predicted upside of 812.88% based on their 12-month stock forecasts.
: Outlook Therapeutics has been rated by research analysts at Ascendiant Capital Markets, and BTIG Research in the past 90 days.
: Analysts like Outlook Therapeutics more than other "medical" companies. The consensus rating for Outlook Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how OTLK compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Breaking News: Tesla headed to $500… (Ad)

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

This page (NASDAQ:OTLK) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Outlook Therapeutics (OTLK) Stock Forecast & Price Target